When I was diagnosed with idiopathic pulmonary fibrosis (IPF) in 2017, I soon learned the cause and cure were mysteries yet to be solved. I know firsthand how difficult it can be to solve a mystery. Difficult, but seldom impossible. I worked my first career as a special…
Share your PF journey through a patient registry
Researchers have developed an inhalable prototype medicine that may be able to repair lung scarring caused by idiopathic pulmonary fibrosis (IPF) by stimulating the growth of stem cells directly in the lungs, a study reports. The study provides pharmacological proof of concept for an upcoming Phase 1 clinical trial…
The arrival of spring here in Virginia is both a blessing and a curse. Despite the improved weather, I think of it as pollen and mold season. As a longtime sufferer of seasonal allergies, I don’t need the gentle yellow-green tint on vehicles and patio furniture to remind me to…
Enrollment has been completed for a Phase 2b trial that’s testing LYT-100 (deupirfenidone), PureTech Health’s experimental therapy for idiopathic pulmonary fibrosis (IPF). The trial, called ELEVATE IPF (NCT05321420), is assessing the safety, efficacy, and dosing regimen of LYT-100 in 240 adults with IPF, compared with a placebo.
Are you angry? If so, who are you angry with and why? I follow a number of social media groups associated with different rare disease communities. Lately, it seems that people are angry with the very groups advocating on their behalf. I must admit, that intrigues me a bit. When…
Stepping outside of our comfort zone can be an intimidating endeavor. But life often presents us with situations that require us to venture beyond what we’re used to. As I prepare for my first trip away from home since my pulmonary fibrosis (PF) diagnosis four years ago, I find…
Low doses of controlled-release morphine, a natural opioid derived from the opium poppy, may reduce the frequency of daytime cough in people with idiopathic pulmonary fibrosis (IPF), according to data from a Phase 2 clinical trial. In the trial, called PACIFY COUGH (NCT04429516), patients who were experiencing persistent…
“It is only because of your generous gift of life that I am here. This is the hardest letter I have ever composed. Trying to capture the full range of emotions in a single letter to say thank you is more difficult than I imagined.” These are the words that…
Pliant Therapeutics’ Phase 2b BEACON-IPF trial testing bexotegrast, an investigational oral treatment, in people with idiopathic pulmonary fibrosis (IPF) is now a pivotal, adaptive Phase 2b/3 trial. Accepted by European Union and global health authorities, the implementation of the adaptive design is expected to markedly shorten the therapy’s…
Last month, I wrote about my constant battle with lung infections. As a patient with idiopathic pulmonary fibrosis (IPF), a progressive and life-threatening lung disease, I think the condition’s physical manifestations are obvious: respiratory viruses, shortness of breath, and a dry cough. But IPF has implications…
